somatotroph is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-01. Numbers and descriptions here follow the published literature rather than marketing material.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Located on pituitary somatotroph cells |
| Signaling route | cAMP–protein kinase A | Gs-coupled receptor pathway |
| Downstream markers | Growth hormone and IGF-1 | Used as pharmacodynamic readouts |
| Common detection | LC-MS/MS | Separates intact peptide from fragments |
| Typical storage | 2–8 °C, protected from light | Applies to solid form before reconstitution |
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
It was not until he [Trask] had exercised for some time that he could perform any labor ... [H]is neck and back have continued to curve drawing his head downward on his breast. The account of Trask became the first documented case of AS in the United States, owing to its indisputable description of inflammatory disease characteristics of AS and the hallmark of deforming injury in AS. In the late nineteenth century, the neurophysiologist Vladimir Bekhterev of Russia in 1893, Adolf Strümpell of Germany in 1897, and Pierre Marie of France in 1898 were the first to give adequate descriptions which permitted an accurate diagnosis of AS prior to severe spinal deformity. For this reason, AS is also known as Bekhterev disease, Bechterew's disease or Marie–Strümpell disease. The word is from Greek ankylos meaning crooked, curved or rounded, spondylos meaning vertebra, and -itis meaning inflammation.
The Greater Manchester Integrated Transport Authority (GMITA) was a local government institution responsible for the strategic direction of passenger transport in Greater Manchester. It existed from 1969 to 1974 as the SELNEC Passenger Transport Authority and was then replaced by Greater Manchester County Council. It was created again in 1986 as the Greater Manchester Passenger Transport Authority. It was renamed in 2008 as the Greater Manchester Integrated Transport Authority. Policy of the authority was delivered by the Greater Manchester Passenger Transport Executive. It was replaced by the Greater Manchester Combined Authority in 2011.
Florey developed a detailed project plan and deployed eight graduate researchers on it, including Sanders, Medawar and Taylor. Florey performed delicate surgery on rabbits to examine the effects of lymphocyte deprivation. The project, not completed for many years, resulted in several papers and advances in the understanding of the immune system. Florey continued with his lysozyme project. Although the MRC had agreed to pay Roberts's salary, it baulked at providing money for a piece of apparatus that he required. Florey then turned to the Rockefeller Foundation for assistance, and was provided with US$1,250 (about £320)(equivalent to $29,000 in 2025). Florey and Maegraith harvested lysozyme from animals, and Roberts was able to purify it. Edward Abraham then managed to crystallize it in 1937. Chain and Epstein then studied it and determined that it was a polysaccharidase and, with Gardner's help, were able to determine its structure, and how it acted on polysaccharides. The lysozyme research was successful, but while it was lethal to micrococci, these bacteria are not usually pathogenic, and were of little concern to medicine.
The only drug currently approved for stroke treatment is tPA, which can cause dangerous brain bleeding. In 2005, Griffin et al proposed using Activated Protein C in conjunction with tPA to protect the brain from tPA’s harmful side-effects. APC activates protease-activated receptor 1 (PAR-1), which plays a role in the interaction of coagulation and inflammation. The 3K3A-APC was designed to have more activity at protease-activated receptor 1 (PAR-1) and less anticoagulative effect than activated protein C. The phase 2 trial, RHAPSODY, was performed in the lab of Berislav Zlokovic, the scientific founder of ZZ Biotech, to determine safety and tolerability of the drug. A phase 3 $30 million trial, RHAPSODY-2, was planned to determine safety and efficacy for treatment of ischemic stroke. However, on November 16, 2023, the National Institutes of Health (NIH) paused the start of the human trial of 3K3A-APC after an investigation by Science Magazine.
NpCl4 + 4 KC5H5 → Np(C5H5)4 + 4 KCl It is soluble in benzene and THF, and is less sensitive to oxygen and water than Pu(C5H5)3 and Am(C5H5)3. Other Np(IV) cyclopentadienyl compounds are known for many ligands: they have the general formula (C5H5)3NpL, where L represents a ligand. Neptunocene, Np(C8H8)2, was synthesized in 1970 by reacting neptunium(IV) chloride with K2(C8H8). It is isomorphous to uranocene and plutonocene, and they behave chemically identically: all three compounds are insensitive to water or dilute bases but are sensitive to air, reacting quickly to form oxides, and are only slightly soluble in benzene and toluene. Other known neptunium cyclooctatetraenyl derivatives include Np(RC8H7)2 (R = ethanol, butanol) and KNp(C8H8)·2THF, which is isostructural to the corresponding plutonium compound. In addition, neptunium hydrocarbyls have been prepared, and solvated triiodide complexes of neptunium are a precursor to many organoneptunium and inorganic neptunium compounds.
Sources: en.wikipedia.org
Later, in 1687 in the Philosophiæ Naturalis Principia Mathematica, Newton showed mathematically that in an elastic fluid consisting of particles at rest, between which are repulsive forces inversely proportional to their distance, the density would be directly proportional to the pressure, but this mathematical treatise does not involve any Mariott temperature dependence and is not the proper physical explanation for the observed relationship. Instead of a static theory, a kinetic theory is needed, which was developed over the next two centuries by Daniel Bernoulli (1738) and more fully by Rudolf Clausius (1857), Maxwell and Boltzmann. This law was the first physical law to be expressed in the form of an equation describing the dependence of two variable quantities.
== Detroit Lions == It has been said that Detroit Lions' announcer Van Patrick applied the nickname "Fearsome Foursome" to the Lions front four as early as 1960, when the Lion defensive line consisted of ends Bill Glass and Darris McCord, and tackles Alex Karras and Roger Brown. Other reports state that sportswriter Bruno Kerns of the Pontiac Press first used the Fearsome Four nickname for the Lions' defensive line in 1960. The Fearsome Foursome name for the Lions' defensive line continued after Sam Williams replaced Glass in 1962; Glass being traded to the Cleveland Browns for quarterback Milt Plum after the 1961 season. Other than 1963, McCord, Karras, Brown and Williams started together from 1962 through 1965; until Williams was taken by the Atlanta Falcons in the 1966 expansion draft. Karras missed the 1963 season as he was suspended in connection with alleged gambling. Their most well-known game was the 1962 "Thanksgiving Day Massacre" game against the Green Bay Packers, where they sacked Bart Starr 11 times (seven by Brown) and broke the Packers 12-game winning streak. The group's early defensive coordinator was future Pro Football Hall of Fame head coach Don Shula. Karras is in the Pro Football Hall of Fame. The 6 ft 5 in (1.96 m) 300 pound (136 kg) Brown, was one of the first NFL lineman to play at 300 pounds or more, with the speed and agility to make him highly effective at that weight. Brown was named to the Pro Bowl as a Lion from 1962 through 1966 and first-team All-Pro twice (1962-63).
=== Aviation === In 2016, researchers developed a prototype de-icing system that incorporated unzipped carbon nanotube graphene nanoribbons in an epoxy/graphene composite. In laboratory tests, the leading edge of a helicopter rotor blade was coated with the composite, covered by a protective metal sleeve. Applying an electrical current heated the composite to over 200 °F (93 °C), melting a 1 cm (0.4 in)-thick ice layer with ambient temperatures of a -4 °F (-20 °C).
== Function == SPINK functions as a competitive inhibitor of trypsin, which is a protease that can activate other proteases. It has been shown to prevent premature activation of pancreatic enzymes. Monitor peptide binds to intestinal epithelial cells and induces CCK-release, which enhances pancreatic secretion in the presence of nutritional protein in the duodenum. When all nutritional protein is digested, monitor peptide is bound by trypsin and subsequently degraded, resulting in decreasing CCK-release and a reduction of pancreatic secretion. Similar to CCK-releasing peptide (CCK-RP, homologous to DBI), it is trypsin sensitive and stimulates CCK release. It is possible that it also stimulates the growth of intestinal epithelial cells.
This is a shortened version of the thirteenth chapter of the ICD-9: Diseases of the Musculoskeletal System and Connective Tissue. It covers ICD codes 710 to 739. The full chapter can be found on pages 395 to 415 of Volume 1, which contains all (sub)categories of the ICD-9. Volume 2 is an alphabetical index of Volume 1. Both volumes can be downloaded for free from the website of the World Health Organization.
Sources: en.wikipedia.org
Constant hunger Unexplained weight loss Weight gain Flu-like symptoms, including weakness and fatigue Blurred vision Slow healing of cuts or bruises Tingling or loss of feeling in hands or feet Recurring gum or skin infections Recurring vaginal or bladder infections Acetone odor during diabetic ketoacidosis (DKA)
Steven Ruggles (born May 8, 1955) is Regents Professor of History and Population Studies at the University of Minnesota, and the director of the IPUMS Center for Data Integration. He received a 2022 MacArthur "Genius" award. Ruggles is best known as the creator of IPUMS, the world's largest population database. IPUMS provides information about two billion people residing in 159 countries between 1703 and the present, including every respondent to the surviving U.S. censuses of 1790 to 1950. He served as founding director of the Minnesota Population Center from 2000 to 2016 and the Institute for Social Research and Data Innovation from 2016 to 2023. He served as the 2015 President of the Population Association of America, the first historian to hold the position. He also served as President of the Association of Population Centers (2017–2018) and President of the Social Science History Association (2018–2019). He has been active on many national advisory and study committees, including the Census Bureau Scientific Advisory Committee; the National Science Foundation Social, Behavioral, and Economic Sciences Advisory Committee; the National Science Foundation Advisory Committee for CyberInfrastructure; and the National Academy of Sciences Board on Research Data and Information. Ruggles completed a BA at the University of Wisconsin–Madison (1978), followed by at the University of Pennsylvania an MA (1982) and PhD (historical demography, 1984).
Tui na (推拿) is a form of massage, based on the assumptions of TCM, from which shiatsu is thought to have evolved. Techniques employed may include thumb presses, rubbing, percussion, and assisted stretching.
In December 1966, the UN further iterated that these sanctions were mandatory, and member states were explicitly barred from purchasing Rhodesian export goods, namely tobacco, chromium, copper, asbestos, sugar, and beef. The British government, having already adopted extensive sanctions of its own, dispatched a Royal Navy squadron to monitor oil deliveries in the port of Beira in Mozambique, from which a strategic pipeline ran to Umtali in Rhodesia. The warships were to deter "by force, if necessary, vessels reasonably believed to be carrying oil destined for (Southern) Rhodesia". Some Western nations, such as Switzerland and West Germany, which were not UN member states, continued to conduct business openly with Rhodesia – the latter remained the Smith government's largest trading partner in Western Europe until 1973, when it was admitted to the UN. Japan remained the chief recipient of Rhodesian exports outside the African continent, and Iran also supplied oil to Rhodesia in violation of the embargo. Portugal served as a conduit for Rhodesian goods, which it exported through Mozambique with false certificates of origin. South Africa, too, refused to observe the UN sanctions. In 1971, the Byrd Amendment was passed in the United States, permitting American firms to go on importing Rhodesian chromium and nickel products as normal. Despite the poor showing of sanctions, Rhodesia found it nearly impossible to obtain diplomatic recognition abroad. In 1970, the United States declared it would not recognise UDI "under [any] circumstances".
Sources: en.wikipedia.org
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.
IGF-1 reflects growth hormone activity but changes slowly and can be measured from one sample. Growth hormone itself is pulsatile, which makes single measurements hard to interpret.
The receptor pathway is well described, but how individual responses vary and what governs long-term outcomes remain open questions. Reported differences across studies are often attributed to assay and population factors.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.